Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 28/06/2024 BST 5-day change 1st Jan Change
47.66 USD +0.91% Intraday chart for Ionis Pharmaceuticals, Inc. +13.94% -5.79%
Sales 2024 * 599M 47.27B Sales 2025 * 765M 60.42B Capitalization 6.95B 549B
Net income 2024 * -572M -45.16B Net income 2025 * -519M -40.97B EV / Sales 2024 * 11.2 x
Net cash position 2024 * 219M 17.33B Net Debt 2025 * 212M 16.74B EV / Sales 2025 * 9.36 x
P/E ratio 2024 *
-12.6 x
P/E ratio 2025 *
-14.5 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating MT
Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review MT
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review MT
Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed CI
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities... Our Logo
Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen?s Genetic Medicines & RNA Summit, Jun-20-2024 03:30 PM
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific MT
Ionis Pharmaceuticals, Inc. Announces Expand Licensing Agreement with Otsuka Pharmaceutical Co., Ltd CI
Investors need more time to assess Fed comments Our Logo
Bernstein Upgrades Ionis Pharmaceuticals to Market Perform From Underperform, Adjusts Price Target to $44 From $37 MT
ANALYST RECOMMENDATIONS : Adobe, Bank of America, Boeing, Nvidia, Wise... Our Logo
Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 through Jun-13-2024
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema MT
More news
1 day+0.91%
1 week+13.94%
1 month+26.86%
3 months+9.94%
6 months-5.79%
Current year-5.79%
More quotes
1 week
44.36
Extreme 44.36
47.86
1 month
37.93
Extreme 37.925
47.86
Current year
35.95
Extreme 35.95
54.44
1 year
35.95
Extreme 35.95
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 30/06/12
Founder 62 09/01/89
Director of Finance/CFO 62 30/04/00
Members of the board TitleAgeSince
Chairman 72 02/02/14
Founder 62 09/01/89
Director/Board Member 70 09/06/19
More insiders
Date Price Change Volume
28/06/24 47.66 +0.91% 2,626,198
27/06/24 47.23 -0.99% 1,982,856
26/06/24 47.7 +1.49% 2,531,312
25/06/24 47 +5.19% 2,670,767
24/06/24 44.68 +6.81% 4,717,222

Delayed Quote Nasdaq, June 28, 2024 at 09:00 pm

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
47.66 USD
Average target price
58.51 USD
Spread / Average Target
+22.77%
Consensus